BB Biotech AG reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported revenue was CHF 0.001 million compared to CHF 0.1 million a year ago. Net loss was CHF 157.17 million compared to CHF 48.39 million a year ago. Basic loss per share from continuing operations was CHF 2.87 compared to CHF 0.89 a year ago. Diluted loss per share from continuing operations was CHF 2.87 compared to CHF 0.89 a year ago.
For the nine months, revenue was CHF 44.5 million compared to CHF 0.622 million a year ago. Net income was CHF 16.24 million compared to net loss of CHF 315.72 million a year ago. Basic earnings per share from continuing operations was CHF 0.3 compared to basic loss per share from continuing operations of CHF 5.76 a year ago. Diluted earnings per share from continuing operations was CHF 0.3 compared to diluted loss per share from continuing operations of CHF 5.76 a year ago.